Teva Specialty & Biosimilar Pipeline

By development stage – as of October 31, 2022


Teva’s Global R&D organization helps propel the company’s mission to be a global leader in generics and biopharmaceuticals. From early development to commercial launch of Active Pharmaceutical Ingredients (API), small molecules, novel biologics and biosimilars, our uniquely integrated “One Teva” drug development model combines our strengths in API and generics with our knowledge of innovative drug development. We understand the many ways that health impacts people’s lives, and will continue to invest in new breakthrough treatments while expanding access to high-quality medicines for our patients across the globe.

Technology Platforms:

Novel Biologics
Small Molecules
Digital Respiratory
Biosimilars

Under Regulatory Review

Biosimilar to Humira®
(adalimumab) 01

Risperidone LAI Schizophrenia

Biosimilar to Lucentis® (ranibizumab) 04

Pre Submission

Biosimilar to Stelara® (Ustekinumab) 01

Digihaler®
(budesonide and formoterol
fumarate dihydrate)
(EU)

Digihaler® 
(beclomethasone dipropionate HFA)
(US)

Phase 3

Biosimilar to Eylea® (aflibercept)

Deutetrabenazine 02
Dyskinesia in Cerebral Palsy

Biosimilar to Prolia® (denosumab)

Biosimilar to Xolair® (omalizumab)

TV-44749
Schizophrenia

Phase 2

TEV-48574
Inflammatory Bowel Disease

Phase 1

TEV-53408
Gastrointestinal

TEV- 56286 03
Multiple System Atrophy

TEV-56248
Respiratory

Pre-clinical

TEV-46000
Neuroscience

TEV-56278
Oncology

TEV-56192
Immunology

TEV-56279
Pain

TV-48438
Schizophrenia

TEV-56287 04
Parkinson’s Disease

TEV-56285

TEV-54142

TEV-56191

TEV-56261

TEV-56282 01

TEV-56284 01

TEV-56289

Novel Biologics
Small Molecules
Digital Respiratory
Biosimilars

Download a PDF version of Teva Specialty and Biosimilar Pipeline

Download PDF

Teva specialty & biosimilar pipeline by development stage, excluding country / regional launches of products submitted or under review in new markets.

Pipeline is current as of October 31, 2022

  1. Back to contents.

    In collaboration with Alvotech for the US market.

  2. Back to contents.

    This use is investigational.

  3. Back to contents.

    In collaboration with MODAG.

  4. Back to contents.

    In collaboration with BioEq in UK (marketed as ONGAVIA®), EU (to be marketed as RANIVISIO®) and Canada (submitted).